Regentis Biomaterials (NYSE American: RGNT) announced plans to begin European surgeon training activities in the third quarter of 2026 as part of preparations for the commercial rollout of GelrinC(R), its CE Mark-approved treatment for knee cartilage lesions. The hands-on program will provide orthopedic surgeons with practical experience using the company’s cell-free implant and is expected to begin at Humanitas Research Hospital in Milan, Italy, with additional sessions planned across Europe.
The company said the training initiative is a key step in its European commercialization strategy and will be supported by a network of Centers of Excellence focused on surgeon education, clinical guidance and knowledge sharing. GelrinC is designed as a ready-to-use, single-step implant procedure for knee cartilage repair, and Regentis believes expanding physician familiarity with the technology will support adoption as the product enters broader clinical use.
The full press release is available at https://ibn.fm/QOWWK. Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore health and enhance quality of life. With an initial focus on orthopedic treatments, Regentis’ Gelrin platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased tissue including inflamed cartilage and bone. Regentis’ lead product GelrinC(R), is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing the surrounding cells to regenerate the cartilage in a controlled and synchronous process. GelrinC(R) aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S. where no off-the-shelf treatment is available.
The importance of this announcement lies in its potential to address a significant unmet medical need. Knee cartilage lesions affect hundreds of thousands of patients annually, and current surgical options often involve complex procedures with lengthy recovery times. GelrinC offers a single-step, off-the-shelf solution that could simplify treatment and improve outcomes. The European training program is a critical milestone in bringing this technology to surgeons and patients, indicating that Regentis is moving from clinical development to commercial reality. Successful adoption in Europe could also pave the way for future regulatory submissions in other markets, including the United States.
Forward-looking statements in this article involve risks and uncertainties as detailed in the company's SEC filings, and undue reliance should not be placed on them. The terms of use and disclaimers are available at http://IBN.fm/Disclaimer.
